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Abstract
Background: AFTER (Atrial Fibrillation in Turkey: Epidemiologic Registry) is a prospec-
tive, multicenter study designed with the aim of describing the prevalence and epidemiology of 
AF practice in Turkey. This study aims to evaluate stroke risk in non-valvular atrial fi brilla-
tion (AF) and anticoagulant drug utilization within conformity to AF guidelines. 
Methods: Patients were recruited in 17 referral hospitals refl ecting all the population of 
7 geographical regions of Turkey. 2242 consecutive patients who had been admitted with AF 
on ECG were included in the study. 1745 of these patients, who had non-valvular AF, were 
included in the statistical evaluation. Stroke risk was evaluated with the CHA2DS2-VASc score.
Results: The average age of participants was determined to be 69.2 ± 11.5 years (56% 
female). Persistent-permanent AF was found to be the most common type of non-valvular 
AF (78%). The most common comorbid disorder was hypertension (73%). It was found that 
oral anticoagulant therapy was used by 40% of all patients, 37% of whom had effective INR 
(2.0–3.0). Upon multivariate analysis, age was found to be the only independent predictor 
of stroke among the variables’ effects on thromboembolic events that created CHA2DS2-VASc 
abbreviations (OR 1.026, p < 0.001).
Conclusions: These results suggest that stroke risk scores should be thoroughly heeded 
based on guidelines, and that anticoagulation must be applied according to their guidance. 
(Cardiol J 2013; 20, 4: 447–452)
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Introduction
While atrial fi brillation (AF) is the most com-
mon rhythm disorders observed in our clinical 
practice, its prevalence in general population is 
1–2% [1]. As an important cause of cardiovascular 
mortality and morbidity with progressively incre-
asing prevalence, AF has become a serious health 
issue recently. In accordance with the increasing 
and ageing world population, the prevalence of 
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AF and AF related adverse events, especially 
thromboembolic events, increases. Therefore, 
current guidelines recommend anticoagulant tre-
atment in patients with moderate to high risk of 
thromboembolic events [1]. These patients have 
high scores; a score evaluation system using 
a 9 point scale (9-point score evaluation) defi ned as 
CHA2DS2-VASc (cardiac failure, hypertension, age 
≥ 75 (doubled), diabetes, stroke (doubled), vascular 
disease, age 65–74 and sex category [female]) acro-
nym [2]. In our country, the studies conducted on 
AF, stroke and oral anticoagulant usage are mostly 
unicenter studies with a limited number of patients 
and CHA2DS2-VASc score wasn’t included [3–5]. 
Since the multicenter studies have been conducted 
in western and far eastern populations, they do not 
refl ect the characteristics of the country [6–10].
The aim of this study is to determine the stro-
ke risk of the patients with non-valvular AF, using 
CHA2DS2-VASc score based on the records of the 
multicenter, prospective Atrial Fibrillation in Tur-
key: Epidemiologic Registry (AFTER) study and 
to evaluate the profi le of anticoagulant medication 
use in these patients and the accordance with the 
guidelines.
Methods
Study design and patient selection
2242 consecutive patients admitted to the 
cardiology outpatient clinics of 17 different tertia-
ry health care centers with at least one AF attack 
determined on electrocardiographic examination. 
They were included in the study in a manner of 
refl ecting the population of all geographic regions 
of Turkey [11]. These centers were interviewed 
and informed about the number of patients that 
they should admit to the study according to the 
population of the city. The inclusion criteria were 
determined as “all consecutive patients over 
18 years of age who applied to the cardiology outpa-
tient clinics with at least one attack of AF identifi ed 
on electrocardiographic examination”. Emergency 
admittances, inpatients, patients who had refused 
to be included in the study or had not signed the 
consent form were excluded from the study. Basic 
demographic data and medical treatments of the 
patients were assessed. While the patients were 
being assessed by a cardiologist, the data obtained 
were being recorded to the patient registry form 
prepared for the study. Stroke risk was evalua-
ted by CHA2DS2-VASc score [2]. CHA2DS2-VASc 
depends on a point scoring system that gives 2 
points stroke and/or transient ischemic attack and 1 
point for each of the following factors: age between 
65 and 74 years, history of hypertension, diabetes, 
recent cardiac failure, vascular disease (myocardial 
infarction, complex atheromatous plaque, prior 
revascularization, amputation due to peripheral ar-
tery disease or peripheral artery disease including 
angiographic results of peripheral artery disease) 
and female gender [2]. In terms of stroke risk, 
the patients were divided into two groups as high 
risk patients and low risk patients. The patients 
underwent routine electrocardiographic screening 
for the assessment of heart failure. Hypertension 
was described as blood pressure measurement 
> 140/90 mm Hg, prior diagnosis of hypertension 
or being on antihypertensive treatment. Diabetes 
mellitus was described as a fasting blood glucose 
level of > 126 mg, prior diagnosis of diabetes mel-
litus or being on antidiabetic treatment. A standard 
registration form was fi lled for every patient and 
a consent form was signed by the patients. Ethics 
Committee consent of the study coordinating cen-
ter was obtained.
Statistical analysis
Statistical Package for Social Sciences soft-
ware (SPSS 12, Chicago, IL, USA) was used for the 
data analysis. Normality analyses were assessed 
using Kolmogorov-Smirnow and Shapiro-Wilks 
methods and data consistent with a normal distri-
bution were given as mean ± standard deviation 
and data inconsistent with a normal distribution 
were given as median (minimum–maximum). In 
the quantitative comparison of the data, normally 
disturbed parameters between the two groups 
were compared using student t test and abnormally 
disturbed parameters between the two groups were 
compared using Mann-Whitney U test. Chi-square 
test was used for the comparison of qualitative data. 
The independent effect of the variables constituting 
the CHA2DS2-VASc acronym on the thromboembo-
lic event was assessed using multivariate analysis. 
A p value of < 0.05 was considered signifi cant.
Results
1745 patients with non-valvular AF were 
included in the statistical evaluation. Demogra-
phic characteristics of the patients included in the 
study are presented in (Table 1). The mean age of 
the patients was determined as 69.2 ± 11.5 years. 
78% of the patients with non-valvular AF had per-
sistent/permanent type of AF. 56% of the patients 
with AF were female. Hypertension was the most 
common co-morbidity in patients with AF (73%). 
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Among other concomitant risk factors, while the 
incidences were determined as 31% for cardiac 
failure, 30% for vascular disease and 24% for diabe-
tes mellitus, smoking was observed in 13% of the 
patients. A history of stroke was detected in 15% 
of all patients. When the patients were grouped 
according to the stroke risk based on CHA2DS2-
-VASc score, 87% of the patients were determined 
to have high risk, 9% intermediate risk and 4% low 
risk. When the patients of low and intermediate 
risk groups were compared with the patients of 
high risk group, statistically signifi cant differences 
were observed in all demographic characteristics 
with the exception of body mass index. As expec-
ted, in the high risk group, the rates of the variab-
les constituting CHA2DS2-VASc acronym were 
higher. However, the rate of labile international 
normalized ratio (INR) was higher and the mean 
ejection fraction (EF) was lower (Table 1). As the 
CHA2DS2-VASc score increased, the rate of stroke 
increased (Fig. 1).
The only independent risk found was age, 
in the multivariate analysis assessing the in-
dependent effects of the variables constituting 
the CHA2DS2-VASc acronym, on the thromboem-
bolic event (OR = 1.026; 95% CI 1.013–1.039; 
p < 0.001) (Table 2).
When the patients were assessed in terms of 
anticoagulant/antiplatelet medication profi le, 25% of 
the patients were on warfarin treatment alone, 15% 
of the patients were on warfarin + acetylsalicylic 
acid (ASA) treatment, 42% were on ASA treatment 
alone and 18% of the patients were not using any of 
these treatment options. The use of oral anticoagu-
lant/antiplatelet medications according to the stroke 
risk groups are shown in Figure 2. Accordingly, 
though it was not necessary, 23% of the individuals 
with low risk were using warfarin. However, 58% 
of the patients were not on anticoagulant treatment.
When the whole cohort is considered, whilethe 
patients on oral anticoagulant treatment constitu-
ted 40% of all patients, effective INR level (2.0–3.0) 
was achieved only in 37% of these patients. When 
the patients with high risk, according the CHA2DS2- 
-VASc score, were assessed, the most common 
cause of not receiving anticoagulation therapy was 
the medication not being prescribed by the physi-
cian (70%). This was followed by socioeconomic 
reasons with a percentage of 16% and medical 
contraindications with a percentage of 7%. Reasons 
related to the patients were refusal of treatment 
with a percentage of 4% and discontinuation of the 
treatment with a percentage of 3%.
Discussion
The present study is a multicenter, prospecti-
vely designed study of non-valvular AF. According 
Table 1. Demographic characteristics of the patients.
Variable Low-intermediate
CHA2DS2-VASc score 
(n = 227)
High
CHA2DS2-VASc score 
(n = 1518)
P
Age [years] 54.6 ± 11.1 71.4 ± 9.8 < 0.001
Female 55 929 < 0.001
Body mass index 27.8 ± 4.4 28.0 ± 5.5 0.490
AF type: < 0.001
First attack 40 (18%) 51 (3%)
Paroxysmal 76 (34%) 213 (14%)
Persistent 19 (8%) 245 (16%)
Permanent 92 (40%) 1009 (67%)
Hypertension 55 (24%) 1219 (80%) < 0.001
Heart failure-LV dysfunction 15 (7%) 522 (34%) < 0.001
Diabetes mellitus 6 (3%) 412 (27%) < 0.001
Vascular disease 12 (5%) 510 (34%) < 0.001
Stroke-TIA-thromboembolism 0 266 (18%) < 0.001
History of stroke 0 216 (14%) < 0.001
Labile INR 9 (4%) 161 (11%) 0.002
Effective INR (n = 702) 31 (50%) 231 (36%) 0.031
Ejection fraction 58.3 ± 8.7 51.2 ± 12.8 < 0.001
AF — atrial fibrillation; LV — left ventricular; TIA — transient ischemic attack; INR —  international normalized ratio
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Figure 2. The use of oral anticoagulant/antiplatelet medications according to the stroke risk groups; ASA — acetylsa-
licylic acid.
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Table 2. Logistic regression analysis of the independent predictors of stroke/transient ischemic attack/
/thromboembolic events.
Variable Odds ratio 95% confidence interval P
Age 1.026 1.013–1.039 < 0.001
Sex 1.105 0.839–1.455 0.479
Hypertension 1.257 0.909–1.737 0.166
Heart failure 0.955 0.704–1.296 0.768
Vascular disease 1.205 0.893–1.625 0.222
Diabetes mellitus 1.111 0.816–1.513 0.504
Figure 1. The relationship between CHA2DS2-VASc scores and number of patients with stroke; *percentage of stroke.
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to the analysis of the preliminary data, 4/5 of AF 
cases were included in the persistent/permanent 
group. The frequency in females was higher than 
in males. The most common concomitant risk 
factor was hypertension. According to CHA2DS2-
-VASc score, while 87% of the patients were high 
risk patients, only 42% of these patients were on 
oral anticoagulant treatment. The major reason for 
not receiving oral anticoagulant in spite of medical 
indication was determined as physician’s neglect.
One of the results of the AFTER study that 
differ from that of the literature was the deter-
mination of an incidence in females surpassing 
the incidence in males with a percentage of 22%. 
However, the incidence of AF was 1.5 to 2 times 
higher in females than in males according to the 
records of Framingham studying American So-
ciety and Euro Heart Survey studying European 
societies [12, 13]. Although our results appear 
to contradict these data, they support the data of 
TEKHARF study (Cardiac Diseases and Risk Fac-
tors in Adults in Turkey), the epidemiological study 
on AF in Turkey [14]. When assessed according 
the geographical regions of Turkey, no difference 
was detected between female/male distribution. 
This observation suggests that the aforementioned 
result is a demographic characteristic specifi c to 
our society. In a study of 1084 patients with non-
-valvular AF conducted by Lip et al. [2] — the one 
who introduced the CHA2DS2-VASc risk score to 
the literature — the most common comorbidity 
in AF was demonstrated as hypertension. In our 
study, while hypertension was observed in a simi-
lar rate, vascular disease was observed in a lower 
frequency and heart failure, history of stroke and 
diabetes mellitus were observed at a higher fre-
quency.
Euro Heart Survey Investigators showed 
that, when assessing the independent effect of all 
potential risk factors on thromboembolic events, 
female gender was the only signifi cant associated 
factor (OR = 2.53; 95% CI 1.08–5.92; p < 0.29). 
However, in our cohort, the multivariate analysis 
revealed age as the only signifi cant factor.
In the Euro Heart Survey study [15] of 2706 
patients with AF, when the patients were assessed 
in terms of oral anticoagulant/antiplatelet medica-
tion profi le, 57% of all patients were on warfarin 
treatment alone, 7% were on warfarin + ASA 
treatment, 27% were on ASA treatment alone, 
and 9% of the patients were not using any of the-
se treatment options. In our study, while the rate 
of oral anticoagulant use was 40%, ASA use was 
approximately 2 times higher. In the J-RYHTHM 
[6] study which was conducted in Japan, while the 
rate of anticoagulant use was 87%, the rate of ASA 
use was found to be 22%. In the subgroup analysis 
[16] of the same study, 89% of the 6324 patients 
with non-valvular AF were on warfarin treatment 
and 23% were on ASA treatment. In this study too, 
only in 34% of the patients the effective INR level 
(2.0–3.0) was achieved. When the data of our study 
were compared with these results, while the rates 
of warfarin use were dramatically lower, the effec-
tive INR levels were achieved at a rate surprisingly 
similar to the rate of the aforementioned study. 
When considering that the most common cause of 
not receiving anticoagulant medication was that in 
70% of cases the medication was not prescribed 
by the physician, one may suppose that our phy-
sicians attach a particular importance to warfarin 
monitoring and surpassing the value reported in 
the literature. However, the detection of the rate of 
unnecessary use of warfarin as 23% in the low risk 
group reveals that the guidelines are not followed 
in the anticoagulation management. In this way 
it emphasizes the important barrier concerning 
warfarin. Therefore, novel anticoagulants will be 
welcomed in real world practice against stroke 
prevention in patients with AF [17–20].
Conclusions
According to the results of our study, the 
stroke prevalence in patients with non-valvular AF 
was 15% and all of these patients were included 
in high risk group according to the CHA2DS2-VASc 
score. Age was the most powerful independent 
determinant of stroke. The major cause of the 
anticoagulation rate of 40% and the prevalence 
of 37% in achieving the effective INR levels and 
not receiving anticoagulant medication was the 
physician’s neglect. These results suggest that in 
our clinical practice of non-valvular AF, particularly 
in the treatment fi eld, one shall pay more attention 
to the stroke risk scores indicated by guidelines 
and anticoagulation shall be managed according to 
these guidelines.
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